The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms

Cancer

Volumn 101, Issue 12, 2004, Pages 2802-2808

  Liu, Geoffrey ^a   Zhou, Wei ^a   Park, Sohee ^b   Wang, Lisa I ^a   Miller, David P ^a   Wain, John C ^b   Lynch, Thomas J ^a   Su, Li ^a   Christiani, David C ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Building 1 1402 ^*  (United States)

Author keywords

Case control study; Genetic polymorphisms; Lung carcinoma; p53; SOD2; XRCC1

Indexed keywords

ALANINE; AMINO ACID; ARGININE; DNA; GLUTAMINE; PROLINE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; VALINE;

ADULT; AGED; ARTICLE; CANCER STAGING; CASE CONTROL STUDY; CELL TYPE; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; X RAY CROSS COMPLEMENTING GROUP 1 GENE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; SMOKING; SUPEROXIDE DISMUTASE;

EID: 10044269810     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20716     Document Type: Article

References (43)

1. Sun Y, Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic Biol Med, 1990;8:583-599.
2. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis. 2000;21:361-370.
3. Chung-man Ho J, Zheng S, Comhair SA, Farver C, Erzurum SC, Differential expression of manganese superoxide dismutase and catalase in lung cancer. Cancer Res. 2001;61:8578-8585.
4. Robinson BH. The role of manganese superoxide dismutase in health and disease. J Inherit Metab Dis. 1998;21:598-603.
5. Bandy B, Davison AJ. Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging? Free Radic Biol Med. 1990;8:523-539.
6. Zhao Y, Oberley TD, Chaiswing L, et al. Manganese superoxide dismutase deficiency enhances cell turnover via tumor promoter-induced alterations in AP-1 and p53-mediated pathways in a skin cancer model. Oncogene. 2002;21:3836-3846.
7. Li Z, Khaletskiy A, Wang J, Wong JY, Oberley LW, Li JJ. Genes regulated in human breast cancer cells overexpressing manganese-containing superoxide dismutase. Free Radic Biol Med. 2001;30:260-267.
8. Church SL, Grant JW, Ridnour LA, et al. Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc Natl Acad Sci USA. 1993;90:3113-3117.
9. Yan T, Oberley LW, Zhong W, St. Clair DK. Manganese-containing superoxide dismutase overexpression causes phenotypic reversion in SV40-transformed human lung fibroblasts. Cancer Res. 1996;56:2864-2871.
10. Liu R, Oberley TD, Oberley LW. Transfection and expression of MnSOD cDNA decreases tumor malignancy of human oral squamous carcinoma SCC-25 cells. Hum Gene Ther. 1997;8:585-595.
11. Zhong W, Oberley LW, Oberley TD, St. Clair DK. Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene. 1997;14:481-490.
12. Zhang HJ, Yan T, Oberley TD, Oberley LW. Comparison of effects of two polymorphic variants of manganese superoxide dismutase on human breast MCF-7 cancer cell phenotype. Cancer Res. 1999;59:6276-6283.
13. Weinberg RA. Tumor suppressor genes. Science. 1991;254:1138-1146.
14. Frebourg T, Friend SH. The importance of p53 gene alterations in human cancer: is there more than circumstantial evidence? J Natl Cancer Inst. 1993;85:1554-1557.
15. Dulic V, Kaufmann WK, Wilson SJ, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 1994;76:1013-1023.
16. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res. 2001;264:56-66.
17. Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA. DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2001;10:125-131.
18. Thompson LH, West MG. XRCC1 keeps DNA from getting stranded. Mutat Res. 2000;459:1-18.
19. Bohr VA, Stevnsner T, Souza-Pinto NC. Mitochondrial DNA repair of oxidative damage in mammalian cells. Gene. 2002;286:127-134.
20. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. Biochem Biophys Res Commun. 1996;226:561-565.
21. Hiroi S, Harada H, Nishi H, Satoh M, Nagai R, Kimura A. Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. Biochem Biophys Res Commun. 1999;261:332-339.
22. Wang LI, Miller DP, Sai Y, et al. Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk. J Natl Cancer Inst. 2001;93:1818-1821.
23. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092-1100.
24. Liu G, Miller DP, Zhou W, et al. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res. 2001;61:8718-8722.
25. Wu X, Zhao H, Amos CI, et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst. 2002;94:681-690.
26. Weston A, Perrin LS, Forrester K, et al. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev. 1992;1:481-483.
27. Jin X, Wu X, Roth JA, et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis. 1995;16:2205-2208.
28. Biros E, Kalina I, Kohut A, Stubna J, Salagovic J. Germ line polymorphisms of the tumor suppressor gene p53 and lung cancer. Lung Cancer. 2001;31:157-162.
29. Papadakis ED, Soulitzis N, Spandidos DA. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer. 2002;87:1013-1018.
30. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res. 1999;59:2557-2561.
31. Matullo G, Guarrera S, Carturan S, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer. 2001;92:562-567.
32. Abdel-Rahman SZ, El Zein RA. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett. 2000;159:63-71.
33. Duell EJ, Wiencke JK, Cheng TJ, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis. 2000;21:965-971.
34. David-Beabes GL, London SJ. Genetic polymorphism of XRCC1 and lung cancer risk among African-Americans and Caucasians. Lung Cancer. 2001;34:333-339.
35. Park JY, Lee SY, Jeon HS, et al. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:23-27.
36. Zhou W, Liu G, Miller DP, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:359-365.
37. Xu LL, Wain JC, Miller DP, et al. The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev. 2001;10:303-309.
38. Zhou W, Thurston SW, Liu G, et al. The interaction between microsomal epoxide hydrolase polymorphisms and cumulative cigarette smoking in different histological subtypes of lung cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:461-466.
39. Iizuka S, Taniguchi N, Makita A. Enzyme-linked immunosorbent assay for human manganese-containing superoxide dismutase and its content in lung cancer. J Natl Cancer Inst. 1984;72:1043-1049.
40. Piyathilake CJ, Bell WC, Oelschlager DK, Heimburger DC, Grizzle WE. The pattern of expression of Mn and Cu-Zn superoxide dismutase varies among squamous cell cancers of the lung, larynx, and oral cavity. Head Neck. 2002;24:859-867.
41. Kobayashi T, Matsumoto M, Iizuka H, Suzuki K, Taniguchi N. Superoxide dismutase in psoriasis, squamous cell carcinoma and basal cell epithelioma: an immunohistochemical study. Br J Dermatol. 1991;124:555-559.
42. Izutani R, Asano S, Imano M, Kuroda D, Kato M, Ohyanagi H. Expression of manganese superoxide dismutase in esophageal and gastric cancers. J Gastroenterol. 1998;33:816-822.
43. Bandera EV, Freudenheim JL, Vena JE. Alcohol consumption and lung cancer: a review of the epidemiologic evidence. Cancer Epidemiol Biomarkers Prev. 2001;10:813-821.